Telavancin is the first approved lipoglycopeptide for the treatment of skin and soft-tissue infection due to resistant gram-positive bacterial pathogens. Telavancin displays concentration-dependent bactericidal killing and a 7.5-h half-life and postantibiotic effect of 4-6 hours allowing for once-daily dosing. Taste disturbance, nausea, headache, foamy urine, and reversible kidney injury are the most commonly observed adverse events. Similar to daptomycin and linezolid, telavancin is useful in the treatment of resistant bacterial skin and soft-tissue infection and is an alternative for patients who are intolerant of vancomycin.